# A Study Of PF-03463275 As Add-On Therapy In Outpatients With Persistent Negative Symptoms Of Schizophrenia

> **NCT00977522** · PHASE2 · TERMINATED · sponsor: **Pfizer** · enrollment: 207 (actual)

## Conditions studied

- Schizophrenia

## Interventions

- **DRUG:** PF-03463275
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00977522
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2009-11
- **Primary completion:** 2010-09
- **Final completion:** 2010-09
- **Target enrollment:** 207 (ACTUAL)
- **Why stopped:** See termination reason in detailed description.
- **Last updated:** 2012-02-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00977522

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00977522, "A Study Of PF-03463275 As Add-On Therapy In Outpatients With Persistent Negative Symptoms Of Schizophrenia". Retrieved via AI Analytics 2026-07-13 from https://api.ai-analytics.org/clinical/NCT00977522. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*